ARCHIVES

EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure.

This article is from The Cancer Letter archive.

Vol. 33 No. 08 | March 2, 2007

Download PDF Visit The Full Archive

Related Articles

Tumor Treating Fields Therapy Increased Three-Year Survival

November 25, 2011

Schmidt’s Term On Cancer Panel Expires, No Word On Reappointment

February 28, 1975

ASCO, ONS Issue Standards For Safe Chemotherapy Administration

October 2, 2009

Tracor Could Earn $186,000 As Prime Contractor On Carcinogenesis Bioassay

April 26, 1974

Phase IIb Trial of CRLX101 Fails Overall Survival Endpoint

March 29, 2013

AACR Changes Its Logo— For The Fifth Time Since 2000

July 11, 2014